<SEC-DOCUMENT>0001144204-19-038565.txt : 20190808
<SEC-HEADER>0001144204-19-038565.hdr.sgml : 20190808
<ACCEPTANCE-DATETIME>20190808161522
ACCESSION NUMBER:		0001144204-19-038565
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190807
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190808
DATE AS OF CHANGE:		20190808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		191009695

	BUSINESS ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv527154_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C.&nbsp;20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): August 7, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>000-26770</B></TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>22-2816046</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(State
        or Other Jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>of
        Incorporation)</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(I.R.S.
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>Identification
        No.)</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>21 Firstfield Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gaithersburg, Maryland 20878</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Address
of Principal Executive Offices, including Zip Code)</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(240) 268-2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Registrant&rsquo;s
telephone number, including area code)</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>(Former name or former
address, if changed since last report.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 33%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Trading Symbol(s)</B></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Common Stock, Par Value $0.01 per share</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">NVAX</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">The Nasdaq Global Select Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>
<BR></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211D1E">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.75in; color: #211D1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: -3in"><FONT STYLE="font-size: 10pt; color: #211D1E">Emerging
growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211D1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #211D1E">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02. Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Second Quarter Financial Results</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On August 7, 2019,
Novavax, Inc. (the &ldquo;Company&rdquo;) issued a press release announcing the Company&rsquo;s financial results for the quarter
ended June 30, 2019. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information
in Items 2.02 and 9.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 89%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tv527154_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tv527154_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt; background-color: white">Press release, dated August 7, 2019, regarding the Company&rsquo;s financial results for the quarter ended June 30</FONT><FONT STYLE="font-size: 10pt">, 2019<FONT STYLE="background-color: white">.</FONT></FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top"><B>NOVAVAX, INC.</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; border-bottom: Black 1pt solid; text-indent: 0; text-align: left; vertical-align: top">/s/ John A. Herrmann III</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; padding: 0; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 5%; text-align: left; vertical-align: top; text-indent: 0">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 35%; text-indent: 0; text-align: left; vertical-align: top">John A. Herrmann III</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; vertical-align: top; text-indent: 0">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">Senior Vice President, General Counsel and Corporate Secretary</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 8, 2019</P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv527154_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 30.75pt; width: 198pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>Novavax
Reports Second Quarter 2019 Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 12pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><I>Agreement
                                         with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu&trade;</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 12pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><I>NanoFlu
                                         pivotal Phase 3 clinical trial expected to initiate in the third quarter of 2019 with
                                         top-line data in the first quarter of 2020</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 12pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><I>Strategic
                                         partnership completed with Catalent; raised $18 million</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 12pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><I>Company
                                         to host conference call today at 4:30 p.m. ET</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>GAITHERSBURG,
MD, August 7, 2019</B> (GLOBE NEWSWIRE) &ndash; Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation
vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter
and six months ended June 30, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;We
made important clinical and strategic progress this quarter, particularly in advancing NanoFlu, our next-generation flu vaccine
candidate,&rdquo; said Stanley C. Erck, President and Chief Executive Officer of Novavax. &ldquo;The agreement reached with the
FDA on our NanoFlu Phase 3 clinical trial design will allow us to leverage the accelerated approval pathway. We are now well-positioned
to deliver top-line Phase 3 data in the first quarter of 2020.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Second Quarter 2019 and Subsequent Operational
Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>NanoFlu&trade;
Program</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Novavax received
input from the U.S. Food and Drug Administration (FDA) on its End-of Phase 2 questions and reached agreement on the Phase 3 clinical
trial design, enabling Novavax to conduct a non-inferiority immunogenicity clinical trial against a licensed quadrivalent comparator.
These data would support the future biologics license application and licensure of NanoFlu via the accelerated approval pathway.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>ResVax&trade;
Program</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Novavax continues
to receive input from global regulatory agencies to solicit input on possible pathways to licensure for ResVax. In Europe, we will
seek formal scientific advice this fall from the European Medicines Agency (EMA). In the U.S., the FDA recommended that Novavax
conduct an additional Phase 3 clinical trial to confirm efficacy against medically significant RSV disease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Novavax presented
key efficacy and safety findings at the World Vaccine Congress in Washington, D.C. and at the Annual Meeting of the European Society
for Pediatric Infectious Diseases (ESPID) in Ljubljana, Slovenia from the Prepare trial of ResVax. Additional details on these
presentations are available on our website.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>Corporate</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Novavax and Catalent
Biologics entered into an arrangement under which Catalent purchased Novavax&rsquo; manufacturing equipment and related assets
for approximately $18 million, assumed the property leases to two Novavax product development and manufacturing facilities and
hired approximately 100 of Novavax&rsquo; manufacturing and quality employees. In addition, Catalent will also provide long-term
process development and manufacturing services for specified Novavax programs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Effective May
10, 2019, Novavax completed a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-20.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Financial Results for the Three and
Six Months Ended June 30, 2019 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share and per share information have been
restated to reflect the reverse stock split described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Novavax
reported a net loss of $39.6 million, or $1.69 per share, for the second quarter of 2019, compared to a net loss of $44.5 million,
or $2.37 per share, for the second quarter of 2018. For the six months ended June 30, 2019, the net loss was $82.8 million, or
$3.77 per share, compared to a net loss of $90.8 million, or $5.10 per share, for the same period in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Novavax
revenue in the second quarter of 2019 was $3.4 million, compared to $10.8 million in the same period in 2018. This 69% decrease
was driven by the completion of enrollment of participants in the Prepare trial in the second quarter of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Research
and development expenses decreased 32% to $30.4 million in the second quarter of 2019, compared to $44.5 million for the same period
in 2018. This decrease was primarily due to decreased development activities of ResVax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">General
and administrative expenses increased 17% to $9.6 million in the second quarter of 2019, compared to $8.2 million for the same
period in 2018. The increase was primarily due to higher professional fees and recent stockholders meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Interest
income (expense), net for the second quarter of 2019 was ($2.9) million, compared to ($2.6) million for the same period of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">As
of June 30, 2019, Novavax had $78.2 million in cash, cash equivalents, marketable securities and restricted cash, compared to $103.9
million as of December 31, 2018. Net cash used in operating activities for the first six months of 2019 was $80.6 million, compared
to $106.0 million for same period in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Conference
Call</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Novavax
will host its quarterly conference call today at 4:30 p.m. ET. The dial-in numbers for the conference call are (877) 212-6076 (Domestic)
or (707) 287-9331 (International), passcode 3193866. A replay of the conference call will be available starting at 7:30 p.m. ET
on August 7, 2019 until 7:30 p.m. ET on August 14, 2019. To access the replay by telephone, dial (855) 859-2056 (Domestic) or (404)
537-3406 (International) and use passcode 3193866.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">A
webcast of the conference call can also be accessed via a link on the home page of the Novavax website (novavax.com) or through
the &ldquo;Investor Info&rdquo;/&ldquo;Events&rdquo; tab on the Novavax website. A replay of the webcast will be available on the
Novavax website until November 7, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Influenza</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Influenza
is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death.
Serious illness occurs not only in susceptible populations such as infants, young children and older adults, but also in the general
population largely because of infection by continuously evolving strains of influenza which can evade the existing protective antibodies
in humans. An estimated one million deaths globally each year are attributed to influenza. Current estimates for seasonal influenza
vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately
$3.2 billion in 2015 to $5.3 billion by 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About NanoFlu&trade; and Matrix-M&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">NanoFlu
is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus
system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences.
NanoFlu contains Novavax&rsquo; patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect
by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph
nodes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Accelerated Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Accelerated
approval may be granted for certain biological products that have been studied for their safety and effectiveness in treating serious
or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments. Such an approval will be
based on adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint
that is reasonably likely to predict clinical benefit. For seasonal influenza vaccines, the hemagglutination inhibition (HAI) antibody
response may be an acceptable surrogate marker of activity that is reasonably likely to predict clinical benefit. To be considered
for accelerated approval, a biologics license application for a new seasonal influenza vaccine should include results from one
or more well-controlled studies designed to meet immunogenicity endpoints and a commitment to conduct confirmatory post-marketing
studies of clinical effectiveness in preventing influenza.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About RSV in Infants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Globally,
RSV (respiratory syncytial virus) is the leading viral cause of severe lower respiratory tract disease in infants and young children.
It is the second leading cause of death in children under one year of age. Estimated annual hospitalizations of 1.4 million and
an estimated 27,300 in-hospital deaths were due to RSV acute lower respiratory infection in children under six months of age. RSV
results in a total global economic burden of $6.2 billion annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In
the U.S., RSV is the leading cause of hospitalization of infants, with estimated annual hospitalizations of up to 76,000. While
RSV can impact all infants, babies under six months of age are among those at highest risk, as approximately 77% of all first-year
RSV infections occur before six months. In the U.S., the total economic burden is $2.7 billion annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ResVax&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">ResVax
is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to
protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants
through the first months of life. ResVax is being evaluated in Prepare&trade;, a global Phase 3 clinical trial in 4,636 pregnant
women, at least 3,000 of whom received the vaccine, and their infants. Prepare is supported by an $89.1 million grant from the
Bill &amp; Melinda Gates Foundation (BMGF).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Novavax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Novavax, Inc.
(Nasdaq:NVAX), is a late-stage biotechnology company that drives improved health globally through the discovery, development, and
commercialization of innovative vaccines to prevent serious infectious diseases. ResVax&trade;, its RSV vaccine for infants via
maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent severe lower respiratory tract
infection which is the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu&trade;,
its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved
flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines
the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent
global health needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, visit <FONT STYLE="color: Blue"><U>www.novavax.com
</U></FONT>and connect with us on <FONT STYLE="color: Blue"><U>Twitter</U></FONT> and <FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Statements herein
relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements.
Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual
results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified
under the heading &ldquo;Risk Factors&rdquo; in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and
Quarterly Report on Form 10-Q for the period ended June 30, 2019, as filed with the Securities and Exchange Commission (SEC). We
caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation
to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">NOVAVAX, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(in thousands, except per share information)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 1.5pt">Revenue</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,357</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,773</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,339</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,426</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: right; padding-left: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 1.5pt">Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Research and development</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">30,417</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44,542</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">65,890</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">89,056</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">General and administrative</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">9,606</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,224</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">18,338</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,876</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">40,023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">52,766</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">84,228</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">105,932</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt">Loss from operations</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(36,666</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(41,993</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(76,889</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(85,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt">Interest income (expense), net</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(2,929</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,596</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(5,912</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,468</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Other income (expense)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(8</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">97</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(20</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">130</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 1.5pt">Net loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(39,603</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(44,492</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(82,821</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(90,844</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: right; padding-left: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 1.5pt">Basic and diluted net loss per share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1.69</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2.37</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(3.77</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5.10</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 1.5pt">Basic and diluted weighted average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 0.125in">number of common shares outstanding</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">23,473</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">18,796</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,966</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,828</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SELECTED CONSOLIDATED BALANCE SHEET DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30, 2019</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.9pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">71,995</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">70,154</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4.5pt">Marketable securities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21,980</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 4.5pt">Total restricted cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,240</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,805</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">110,218</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">119,276</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Working capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">68,730</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73,737</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">189,389</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">207,978</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Notes payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">319,899</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">319,187</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.9pt">Total stockholders&rsquo; deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(185,493</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(167,935</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Investors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novavax, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Erika Trahan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Manager, Investor &amp; Public Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>ir@novavax.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">240-268-2000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Westwicke Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Woolford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>john.woolford@westwicke.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">443-213-0506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>Media</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Brandzone/Speak Life Science</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Amy Speak</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>amy@speaklifescience.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">617-420-2461</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !> ET# 2(  A$! Q$!_\0
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MZ\_(.F":_/G_ (*/_P#!3KQE^W_\0)XYY;C1? .GSL=)T&.3"8'2:?&/,E.
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M_1-JWEH?6W@S_@KI^UG\1?%NFZ#H?Q'UG4]8UBY2TL[6#2K)Y)Y7.%4#R?\
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MOV['8JEA,/.O/X8J_P#DOGLC\<P.%J8JO&A'>3_X=_J?1O[1_P#P2!7X<?\
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M?\&O'_'C\7_^NFF?RN*^>XQ_Y%-7Y?\ I2/>X2_Y&=/Y_D?K5.,IQZU_.O\
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MG%D_-CC<Q9B.]>/YK]+X9X9_LV#J56G4EIIT7;_,_/>(^(?[0DJ=)-0B^N[
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M'Q'_ ,%,?^",OA/]N43^)]!EM_"/Q'2+:-0"?Z+JN  JW2 9R ,"1?F&>0P
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M?"0H8F,G*.EU9Z=-VNFA^?YMP?5Q&+E5H245+6SOOUV/YSLXI"P_7%?T9_\
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MX$^V"BBB@!K('&"-WUK\5_\ @Y$_8^'@/XQZ+\7M'M@NG^,%73=:*+A8[V%
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MX9_;9^!6D^-O#4VU;I!#J%D[ S:;=!1YD#C/4$\'HP((ZU_+[7TE_P $Q_\
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8RDMK^?KW/T#A'/7;ZEB&VEL^OI_D?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
